The abstract is read at the publisher; the summary is JClub's.
Panitumumab-based EGFR blockade in SMARCB1-deficient renal medullary carcinoma achieved a 53.9% objective response rate, including 15.4% complete responses, across 26 patients.
- Why it matters: SMARCB1-deficient RMC is ultrarare and lethal with limited options from other renal cell carcinoma therapies, and randomized trials are logistically unfeasible.
- What they did: EGFR was profiled by immunohistochemistry and integrated RNA/chromatin assays, then panitumumab was compared with erlotinib in xenografts and mechanistically tested in vitro and with NK coculture.
- The result: In prospective enrollment of 26 patients across 10 centers, median progression-free survival was 5.8 months and median overall survival was 9.5 months, supporting further prospective validation.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.